News

Ibandronic acid Intravenous for Adults

Who can administer

May be administered by registered competent doctor or nurse/midwife

Important information

  • There are two intravenous ibandronic acid preparations available - Bonviva and Bondronat
  • Bonviva is licensed for the treatment of osteoporosis
  • Bondronat is licensed for the treatment of Tumour Induced Hypercalcaemia, and for the prevention of skeletal related events in patients with breast cancer or bone metastases
  • Only Bonviva is available in GUH, and this preparation should only be used for osteoporosis
  • See under 'Dose' for adjustments required in renal impairment
  • Ensure pre-counselling and baseline assessment for risk of adverse reactions such as osteonecrosis of the jaw and external auditory canal

Available preparations

Bonviva 3mg per 3mL pre-filled syringe

Bondronat 2mg per 2mL vial - not stocked in GUH

Bondronat 6mg per 6mL vial - not stocked in GUH

Reconstitution

Already in solution

Infusion fluids

Not required - product ready for use (Bonviva)

Methods of intravenous administration

Bolus intravenous injection (Bonviva only)

  • Administer over 15 to 30 seconds

Dose in adults

Treatment of osteoporosis in postmenopausal women at increased risk of fracture

  • Give 3mg by bolus intravenous injection every three months

Renal impairment

  • Not recommended for patients with Creatinine clearance less than 30mL/minute

Further information

  • All patients must receive continuous supplemental calcium and Vitamin D
  • Influenza like symptoms have been reported, typically in association with the first dose
  • Existing hypocalcaemia must be corrected before starting Bonviva

Storage

Store below 250C

References

SPC 29/03/2021

Therapeutic classification

Bisphosphonate